Published in Hospital Business Week, July 15th, 2007
This trend article about University of Florence, Italy, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: New research, "Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study," is the subject of a report. "The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week